查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947933

個人化癌症治療市場分析及預測（至2035年）：按類型、產品、服務、技術、適應症、最終用戶、實施類型、階段和解決方案分類

Personalized Cancer Therapies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Deployment, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 312 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

個人化癌症治療市場預計將從2024年的475億美元成長到2034年的1,078億美元，複合年成長率約為9.1%。個人化癌症治療市場是指根據個別基因譜量身定做治療方法，從而提高療效並最大限度地減少副作用。該市場整合了基因組學、生物技術和先進的診斷技術，以開發標靶治療。隨著精準醫療的日益普及，改善患者預後和提高醫療效率的需求正在推動生物標記發現、標靶藥物和伴隨診斷等領域的創新發展。

在基因組學和標靶治療方法進步的推動下，個人化癌症治療市場正在快速發展。免疫療法領域成長最為迅猛，主要得益於查核點抑制劑和CAR-T細胞療法的成功。這些治療方法利用人體自身的免疫系統攻擊癌細胞，正在革新癌症治療。標靶治療是成長第二快的領域，其中激酶抑制劑和單株抗體可根據基因譜提供精準的治療方案。精準醫療根據個別基因標記量身訂做治療方案，正蓬勃發展，並不斷提升個人化癌症治療的療效。伴隨診斷能夠深入了解患者的個人化治療反應，對於最佳化治療效果至關重要。人工智慧在藥物發現和開發中的應用進一步加速了該市場的發展。隨著個人化治療方案日趨完善，以患者為中心的護理理念有望推動癌症治療策略的持續成長和創新。

市場區隔
類型 單株抗體、細胞療法、基因療法、癌症疫苗、溶瘤病毒療法、標靶小分子化合物
產品 生物製藥、生物相似藥、小分子藥物、診斷試劑、伴隨診斷試劑
服務 基因組分析、生物標記檢測、免疫療法服務、臨床試驗服務、諮詢服務
科技 次世代定序、聚合酵素鏈鎖反應、質譜分析、流式細胞技術、奈米技術、CRISPR
適應症 乳癌、肺癌、結腸癌、攝護腺癌、黑色素瘤、白血病
最終用戶 醫院、癌症研究中心、生技公司、製藥公司、學術機構
實施表格 本機部署、雲端部署、混合式部署
步 研究與開發、臨床試驗、商業化和上市後監測
解決方案 治療、診斷和預測解決方案

個人化癌症治療市場正經歷動態變化，各種新產品的推出拓展了治療選擇。市場佔有率的成長主要主導創新治療方法，這些療法承諾根據每位患者獨特的基因譜量身定做個人化治療方法。定價策略也在不斷演變，以體現這些治療方法的高階特性及其顯著改善患者預後的潛力。該市場競爭異常激烈，各大製藥公司都在研發方面投入大量資金以保持競爭優勢。競爭基準分析揭示了競爭格局，主要企業不斷創新以維持自身優勢。監管影響至關重要，嚴格的指導方針規範著個人化療法的核准和商業化。北美和歐洲等關鍵地區的政策制定者正積極致力於制定影響市場動態的法規結構。分析結果表明，基因組學和生物技術的進步以及對精準醫療日益成長的重視正在推動市場擴張。競爭、監管和創新之間的相互作用決定了相關人員在這個快速成長領域中的策略視角。

主要趨勢和促進因素：

個人化癌症治療市場正經歷強勁成長，這主要得益於基因組學和生物技術的進步。一個關鍵趨勢是精準醫療方法的日益普及，該方法根據個體的基因譜量身定做治療方法。這種轉變提高了治療效果，最大限度地減少了副作用，並顯著改善了患者的預後。另一個趨勢是將人工智慧 (AI) 和機器學習融入藥物發現和開發過程。這些技術正在加速識別新的標靶並最佳化治療方案。此外，液態生物檢體技術的興起徹底改變了癌症診斷，實現了對腫瘤動態和治療反應的非侵入性監測。推動這一市場成長的因素包括癌症發病率的上升以及對以患者為中心的醫療保健模式的日益重視。監管機構也透過加快核准流程來支持個人化治療。我們相信，對於那些利用最尖端科技並與學術和臨床研究機構合作開發創新治療方法的公司而言，存在著許多機會。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 細胞療法
    • 基因治療
    • 癌症疫苗
    • 溶瘤病毒療法
    • 標靶小分子化合物
  • 市場規模及預測：依產品分類
    • 生物製藥
    • 生物相似藥
    • 小分子藥物
    • 診斷試劑
    • 伴隨診斷
  • 市場規模及預測：依服務分類
    • 基因組分析
    • 生物標記檢測
    • 免疫療法服務
    • 臨床試驗服務
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • 次世代定序
    • 聚合酵素鏈鎖反應
    • 質譜分析
    • 流式細胞技術
    • 奈米科技
    • CRISPR
  • 市場規模及預測：依指標
    • 乳癌
    • 肺癌
    • 大腸直腸癌
    • 攝護腺癌
    • 黑色素瘤
    • 白血病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症研究中心
    • 生技公司
    • 製藥公司
    • 學術機構
  • 市場規模及預測：依實施類型分類
    • 本地部署
    • 基於雲端的
    • 混合
  • 市場規模及預測：依階段分類
    • 研究與開發
    • 臨床試驗
    • 商業化
    • 上市後監測
  • 市場規模及預測：按解決方案分類
    • 治療方案
    • 診斷解決方案
    • 預測解決方案

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Blueprint Medicines
  • Adaptive Biotechnologies
  • Nant Health
  • G1 Therapeutics
  • C4 Therapeutics
  • Mirati Therapeutics
  • Relay Therapeutics
  • Immuno Gen
  • Harpoon Therapeutics
  • Cellectis
  • Iovance Biotherapeutics
  • Zymeworks
  • Repare Therapeutics
  • Arcus Biosciences
  • Black Diamond Therapeutics
  • Neoleukin Therapeutics
  • Fate Therapeutics
  • Allogene Therapeutics
  • Surface Oncology
  • Kura Oncology

第9章：關於我們

簡介目錄
Product Code: GIS32901

Personalized Cancer Therapies Market is anticipated to expand from $47.5 billion in 2024 to $107.8 billion by 2034, growing at a CAGR of approximately 9.1%. The Personalized Cancer Therapies Market encompasses treatments tailored to individual genetic profiles, enhancing efficacy and minimizing side effects. This market integrates genomics, biotechnology, and advanced diagnostics to develop targeted therapies. As precision medicine gains traction, demand is rising for innovations in biomarker discovery, targeted drugs, and companion diagnostics, driven by the quest for improved patient outcomes and healthcare efficiency.

The Personalized Cancer Therapies Market is evolving rapidly, propelled by advances in genomics and targeted treatment approaches. The immunotherapy segment is the top performer, driven by the success of checkpoint inhibitors and CAR-T cell therapies. These therapies are revolutionizing cancer treatment by harnessing the body's immune system to attack cancer cells. Targeted therapy follows as the second highest performing segment, with kinase inhibitors and monoclonal antibodies offering precise treatment options based on genetic profiles. Precision medicine, which tailors treatment to individual genetic markers, is gaining momentum, enhancing the efficacy of personalized cancer therapies. Companion diagnostics are crucial, providing insights into patient-specific treatment responses and optimizing therapeutic outcomes. The integration of artificial intelligence in drug discovery and development is further accelerating advancements in this market. As personalized approaches become more refined, the focus on patient-centric care is expected to drive continued growth and innovation in cancer treatment strategies.

Market Segmentation
TypeMonoclonal Antibodies, Cell Therapy, Gene Therapy, Cancer Vaccines, Oncolytic Virus Therapy, Targeted Small Molecules
ProductBiologics, Biosimilars, Small Molecule Drugs, Diagnostics, Companion Diagnostics
ServicesGenomic Profiling, Biomarker Testing, Immunotherapy Services, Clinical Trial Services, Consulting Services
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, Flow Cytometry, Nanotechnology, CRISPR
ApplicationBreast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia
End UserHospitals, Cancer Research Centers, Biotechnology Companies, Pharmaceutical Companies, Academic Institutions
DeploymentOn-premise, Cloud-based, Hybrid
StageResearch and Development, Clinical Trials, Commercialization, Post-Market Surveillance
SolutionsTherapeutic Solutions, Diagnostic Solutions, Predictive Solutions

The Personalized Cancer Therapies Market is witnessing a dynamic shift with a diverse range of new product launches enhancing treatment options. Market share is dominated by innovative therapies that promise tailored treatment regimens, aligning with patient-specific genetic profiles. Pricing strategies are evolving, reflecting the premium nature of these therapies and their potential to significantly improve patient outcomes. The market is characterized by robust competition, with major pharmaceutical companies investing heavily in research and development to maintain a competitive edge. Competition benchmarking reveals a landscape where leading firms are continuously innovating to stay ahead. Regulatory influences are pivotal, with stringent guidelines governing the approval and commercialization of personalized therapies. Policymakers in key regions like North America and Europe are actively shaping the regulatory framework, impacting market dynamics. Analytical insights indicate a growing emphasis on precision medicine, with advancements in genomics and biotechnology driving market expansion. The interplay of competition, regulation, and innovation defines the strategic outlook for stakeholders in this burgeoning field.

Geographical Overview:

The personalized cancer therapies market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the charge, driven by cutting-edge research and substantial investment in precision medicine. The presence of leading biotechnology firms and advanced healthcare infrastructure further bolsters this region's dominance. Europe follows, with strong government support and a growing emphasis on personalized healthcare solutions. The region's commitment to innovation and patient-centric approaches enhances its market potential. In Asia Pacific, the market is expanding rapidly, propelled by rising cancer prevalence and increasing healthcare expenditure. Countries like China and India are emerging as key growth pockets due to their large patient populations and improving healthcare systems. Meanwhile, Latin America and the Middle East & Africa are gaining traction as emerging markets. In Latin America, initiatives to improve healthcare access and infrastructure are driving market growth. The Middle East & Africa are recognizing the potential of personalized therapies to address unmet medical needs, presenting lucrative opportunities for market expansion.

The personalized cancer therapies market is navigating a landscape shaped by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, trade tensions with major economies are fostering investments in local biotech innovation to mitigate dependency on foreign technologies. China's strategic pivot towards self-sufficiency is accelerating its development of domestic biopharmaceutical capabilities, while Taiwan's robust biotech sector remains vulnerable to geopolitical uncertainties. Globally, the parent market is experiencing robust growth, driven by advancements in precision medicine and genomic research. By 2035, the market's trajectory will hinge on resilient supply chains and cross-border collaborations. Meanwhile, Middle East conflicts could exacerbate global supply chain disruptions and elevate energy prices, influencing manufacturing costs and distribution strategies within the sector.

Key Trends and Drivers:

The personalized cancer therapies market is experiencing robust growth, driven by advances in genomics and biotechnology. Key trends include the increasing adoption of precision medicine approaches, which tailor treatments based on individual genetic profiles. This shift is enhancing treatment efficacy and minimizing adverse effects, significantly improving patient outcomes. Another trend is the integration of artificial intelligence and machine learning in drug discovery and development processes. These technologies are accelerating the identification of novel targets and optimizing treatment regimens. Furthermore, the rise of liquid biopsy techniques is revolutionizing cancer diagnostics, enabling non-invasive monitoring of tumor dynamics and treatment responses. Drivers include a growing prevalence of cancer and a heightened focus on patient-centric healthcare models. Regulatory bodies are also supporting personalized therapies through expedited approval pathways. Opportunities abound for companies that leverage cutting-edge technologies and collaborate with academic and clinical research institutions to develop innovative treatments.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Cell Therapy
    • 4.1.3 Gene Therapy
    • 4.1.4 Cancer Vaccines
    • 4.1.5 Oncolytic Virus Therapy
    • 4.1.6 Targeted Small Molecules
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Biologics
    • 4.2.2 Biosimilars
    • 4.2.3 Small Molecule Drugs
    • 4.2.4 Diagnostics
    • 4.2.5 Companion Diagnostics
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genomic Profiling
    • 4.3.2 Biomarker Testing
    • 4.3.3 Immunotherapy Services
    • 4.3.4 Clinical Trial Services
    • 4.3.5 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Mass Spectrometry
    • 4.4.4 Flow Cytometry
    • 4.4.5 Nanotechnology
    • 4.4.6 CRISPR
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lung Cancer
    • 4.5.3 Colorectal Cancer
    • 4.5.4 Prostate Cancer
    • 4.5.5 Melanoma
    • 4.5.6 Leukemia
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Cancer Research Centers
    • 4.6.3 Biotechnology Companies
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 On-premise
    • 4.7.2 Cloud-based
    • 4.7.3 Hybrid
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Research and Development
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercialization
    • 4.8.4 Post-Market Surveillance
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Therapeutic Solutions
    • 4.9.2 Diagnostic Solutions
    • 4.9.3 Predictive Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Deployment
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Deployment
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Deployment
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Deployment
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Deployment
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Deployment
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Deployment
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Deployment
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Deployment
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Deployment
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Deployment
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Deployment
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Deployment
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Deployment
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Deployment
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Deployment
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Deployment
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Deployment
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Deployment
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Deployment
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Deployment
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Deployment
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Deployment
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Deployment
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Blueprint Medicines
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Adaptive Biotechnologies
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Nant Health
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 G1 Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 C4 Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Mirati Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Relay Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Immuno Gen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Harpoon Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cellectis
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Iovance Biotherapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Zymeworks
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Repare Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Arcus Biosciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Black Diamond Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Neoleukin Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Fate Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Allogene Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Surface Oncology
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Kura Oncology
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us